pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Janssen-Cilag International N.V
Janssen-Cilag International N.V.
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Inflammatory Conditions, Moderately
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 161
- Drugs
- 159
- Patents
- 0
42756493BLC2003
Phase 2 · small molecule · Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions
42756493BLC2003 for Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Internal code 42756493BLC2003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen-Cilag International N.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions
- Status
- active
- Trials
- 1